CMS creates billing codes for treatment found effective against omicron

By Alia Paavola for Becker’s Hospital Review

CMS released its Medicare payment codes for administering an antibody treatment found effective against the COVID-19 omicron variant.

The payment codes, effective Feb. 11, are for bebtelovimab. The drug was authorized last week by the FDA to treat patients who are at high risk for progression to severe COVID-19 or hospitalization.

There are several new codes:

• Q0222: injection, bebtelovimab, 175 mg
• M0222: intravenous injection, bebtelovimab, including injection and post-administration monitoring
• M0223: intravenous injection, bebtelovimab, including injection and post-administration monitoring in the home or residence